Neurology

 
Two-thirds of Americans with Mental Illness Support Use of Psychedelics, Survey Finds
January 20, 2022

Americans with anxiety, depression, and PTSD would be willing to try ketamine, psilocybin, and MDMA if they worked better than traditional medications, a Harris Poll finds.

Dementia, Falls Screening in Older Adults Increased in Primary Care with Clinician Education, EHR Enhancement
January 13, 2022

Screening of older adults for falls and cognitive impairment should be routine in primary care; a recent study highlights an intervention that could help.

Dabigatran and Warfarin Appear Similarly Protective Against Dementia
November 18, 2021

Patients taking either of the 2 anticoagulants showed no large differences on 4 cognitive test scores at 2 years, according to authors of the GIRAF trial.

Hypnosis for Chronic Neuropathic Pain: A Literature Review
November 10, 2021

In the first review of its kind, authors found encouraging evidence supporting the use of hypnosis for chronic neuropathic pain treatment. Find key results in our new slideshow.

Risk of Early Stroke Increased in Adults who Vape vs Smoke Traditional Cigarettes, Study Finds
November 09, 2021

AHA 2021: E-cigarette users were found to have a 15% higher risk of a cerebrovascular accident at a younger age than those who smoked combustible tobacco cigarettes.

Prioritizing Mental Health: Applying Person-First Approaches to Care
October 26, 2021

When addressing mental health with patients with obesity, a thoughtful approach that balances psychological health and weight loss is critical, explains Dr Ethan Lazarus.

FDA Approves Oral CGRP Inhibitor Atogepant for Prevention of Episodic Migraine
October 01, 2021

The daily oral CGRP inhibitor is the only agent in the class developed specifically for prevention vs acute treatment of episodic migraine.

Mental Health in America: Which States are Happiest?
September 16, 2021

What state has the lowest suicide rate? Which one has the highest share of adult depression? Find the answers and more insights from a nationwide analysis, here.

FDA Approves Intranasal DHE (Trudhesa) for Acute Migraine Treatment
September 14, 2021

The DHE nasal spray delivered pain relief at 2 hours for 66% of patients; 93% of those remained pain-free at 24 hours and 86% at 2 days post-dose.

ESC 2021: Low-sodium Salt Alternative Found to Reduce Risk of Stroke
August 30, 2021

Substituting regular salt with low-sodium alternative was found to reduce the risk of stroke, major cardiovascular events, and death in a new study presented at ESC Congress 2021.